Truist Financial Boosts Dianthus Therapeutics Stock Price Target

Analysts see potential 68% upside for biotech company's shares

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Truist Financial has raised its price target on Dianthus Therapeutics (NASDAQ:DNTH) stock from $63 to $110, representing a potential upside of 68.71% from the stock's current trading price. The brokerage firm maintained its "buy" rating on the biotech company's shares.

Why it matters

This significant price target increase from a major financial institution signals strong confidence in Dianthus Therapeutics' growth prospects and the potential value of its drug pipeline. It could drive increased investor interest and buying pressure for the stock.

The details

In a research note, Truist Financial cited Dianthus Therapeutics' promising drug candidates and clinical progress as reasons for the price target hike. The company is developing DNTH103, a monoclonal antibody currently in Phase 2 trials for treating autoimmune and inflammatory diseases such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

  • Truist Financial issued the updated price target and rating on Monday, March 9, 2026.

The players

Truist Financial

A major U.S. financial services company that provides banking, investments, insurance, and mortgage products and services.

Dianthus Therapeutics

A clinical-stage biotechnology company developing complement therapeutics for severe autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Dianthus Therapeutics' progress with its lead drug candidate DNTH103 as it advances through Phase 2 clinical trials. Positive results could further boost the stock price and validate Truist Financial's bullish outlook.

The takeaway

Truist Financial's substantial price target increase for Dianthus Therapeutics reflects growing Wall Street confidence in the biotech company's ability to develop innovative therapies for difficult-to-treat autoimmune and inflammatory diseases, which could translate to significant shareholder value creation.